CN1115253A - Eye drops - Google Patents
Eye drops Download PDFInfo
- Publication number
- CN1115253A CN1115253A CN 94107398 CN94107398A CN1115253A CN 1115253 A CN1115253 A CN 1115253A CN 94107398 CN94107398 CN 94107398 CN 94107398 A CN94107398 A CN 94107398A CN 1115253 A CN1115253 A CN 1115253A
- Authority
- CN
- China
- Prior art keywords
- ulcer
- macroglobulin
- eye drop
- eye
- eyeball
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The eye drops for curing eyeball surficial inflammation, acute inflammatory affection and refractory or infectious eyeball surficial ulcer with better curative effect is prepared from alpha 2-macroglobulin (2-15%), distilled water or deionized water, and antiseptic.
Description
The invention belongs to medicinal preparation, particularly a kind of α that contains
2The eye drop of-macroglobulin.
To eyeball table inflammation, the general antibiotics that adopts cooperates vitamins and micro-hormone medicine (containing medicament for the eyes) to treat, this therapeutic effect is not satisfactory, especially to the acute inflammation pathological changes, to prolonged property eyeball table ulcer (the alkali burn ulcer that do not heal, radiation ulcer and dystrophoneurosis ulcer) and infective ulcer still do not have satisfied Therapeutic Method, often cause anopia, cause the patient disabled all the life.
The object of the present invention is to provide a kind of α of containing
2The eye drop of-macroglobulin, this eye drop can effectively be treated eyeball table inflammation and effectively be suppressed generation, the development of acute inflammation pathological changes and ulcer, and prolonged ulcer (alkali burn ulcer, radiation ulcer and dystrophoneurosis ulcer) and the infective ulcer of not healing also do not had better curative effect.
Technical solution of the present invention is: a kind of eye drop, it is mainly by α
2-macroglobulin and distilled water or deionized water are formed, wherein α
2-macroglobulin weight percent content is 2-15%.
α in this eye drop
2-macroglobulin weight percent content optimum range is 5-8%.
Contain micro-antiseptic in this eye drop in addition, this antiseptic is nipalgin or thimerosal or bromo geramine.
This eye drop preparation method is: the spissated α of process
2-macroglobulin extracting solution is transferred PH to 5.6-7.2, is diluted to α with distilled water or deionized water
2The weight percent content of-macroglobulin is 2-15%, adds micro-antiseptic, filtration sterilization, and meat soup pipe antibacterial culturing should (one), and rabbit thermal source, toxicity test should (one), and it is no abnormal after 10 days to put sterilizing room, is distributed into eye drop.
Eye drop of the present invention is mainly used in treatment eyeball table inflammation, acute inflammation pathological changes and the prolonged property eyeball table ulcer (alkali burn ulcer, radiation ulcer and dystrophoneurosis ulcer) that do not heal are with antibiotic and with improving some serious antibacterial and treatment viral, fungal infection.
This eye drop using method is every day 4 times, each 1, or take the circumstances into consideration increase and decrease according to clinical needs.
Contained α in this eye drop
2-macroglobulin has multiple function, as have improve the protective action be subjected to irradiation animal dis motility rate and promote hemopoietic tissue according to the back recover, regeneration function; Can remove proteolytic enzyme in the circulation; Can suppress the multiple protein enzyme that the invasion of pathogen and parasite discharges during body, and some virus is had inhibitory action; Have effect, therefore tangible promoting immunity and growth promoting function are arranged in conjunction with macrophage sex factor and nerve growth factor.Recently research shows that also it has the function of SOD content in the rising aqueous humor, the long-term prolonged eyeball table inflammation that does not heal is also had significant curative effect, so use α
2The eye drop that-macroglobulin is made can be eliminated eyeball table inflammation effectively, suppresses the generation and the development of acute inflammation pathological changes and ulcer, shows good curative effect.
Further specify its result of use below in conjunction with clinical case.
Case 1; Appoint * *, man, 19 years old, the Puyang chlor-alkali plant potroom workman of Henan Province.Patient's the first five day work of being admitted to hospital the time is splashed into right eye with 30% sodium hydroxide accidentally, hinder back speed to clinic of factory with the flushing of boric acid water, local hospitalize is changeed in the back, the state of an illness did not have improvement in four days, the decline of carrying out property of vision.Look into after going into my institute: the vision left eye manually/20cm, the bulbar conjunctiva atropurpureus, pale, the edema of cornea is attached most importance to the below, about 1/2 quadrant of limbus of corneae is pale, top may be seen indistinctly anterior chamber and iris, intraocular pressure Tn.
Treatment: dead point cephalosporin associating every day vitamin C; Partial points vitamin C collyrium, cornea are peaceful, subconjunctival injection heparin and white serum treatment, two week back temporos top cornea recover transparent gradually, should the blood supply of quadrant angle film edge improve mutually.Cornea nasal downside position is still pale, and epithelial defect occurs.During the 3rd week, the epithelial defect district enlarges, and has the shallow-layer ulcer of middle section to occur, and add for the 3rd weekend and use eye drop of the present invention, per hour 1 time, the back ulcer reparation of 2 week of medication, the epithelial defect district diminishes gradually, healing at last, vision 0.2 when leaving hospital.
Case 2: the Shen * *, the man, 19 years old, village township, Xunxian, Henan Province Liu He people from village was chief complaint and is admitted to hospital with " overturning of driving causes eyes alkali burn companion visual deterioration three days ".Patient drove small tractor stone transporting ash before three days, overturn accidentally, was embedded under the lime pile of short duration at that time loss of consciousness, awake aftersensation eyes causalgia, blurring of vision, the huge pain of companion's right thigh, handle the shank wound in local hospital, eye is simply flushing only, changes my institute's treatment eye burn.Have an eyesight test: right eye index/30cm, left eye index/1m, the inhomogeneous white casse of cornea of both eyes, right eye is heavier, and the anterior chamber is may be seen indistinctly, and iris is looked and is loseed; The iris of left eye texture is visual to be reached, and the room dodges (+), pupil circle, and crystal is transparent, and the vitreous body optical fundus is fuzzy, eyes intraocular pressure Tn.Diagnosis: the alkali burn of right eye moderate, the slight alkali burn of left eye.
Treatment: intravenous drip lincomycin associating vitamin C, oral indometacin, partial points antibiotic collyrium, the peaceful collyrium of cornea and eye drop of the present invention, after 2 weeks of medication, cornea of left eye recovered part gradually is transparent, and the epithelium healing is good; Epithelial damage appears in right eye temporo below, does not form ulcer, adhere to 4 weeks of medication after, epithelium heals gradually with the new vessels hypertrophy, corneal healing is good.
Case 3: Cui * *, man, 28 years old, the north suburb, Zhengzhou City peasant.Sky surplus right eye is scalded 50 by hot edible oil, the patient buys Drug therapy by oneself, fails to respond to any medical treatment with chloromycetin eyedrops, erythromycin eye ointment, tetracycline cortisone collyrium etc.Come my gate to examine, per hour replace, unite eye drop of the present invention, per hour 1 time to antibiotic tarivid collyrium, rifampicin eye drop.After 2 weeks of medication, ulcer surface diminishes, and secretions reduces, and Shui Chong disappears in the district, ulcer healing gradually, residual corneal facet.Vision is by 0.06 reaching 0.4 at the beginning.
Case 4; Zhao * *, man, 46 years old, electric welder.
Right corner film wound (after the foreign body enucleation) outer court's antibiotic therapy does not see that corneal ulcer takes a turn for the better February, and ulcer surface constantly enlarges, and the back of being admitted to hospital is with eye drop 2 all ulcer surface secretions minimizings of the present invention, and ulcer heals gradually.
Embodiment 1; Spissated α learnt from else's experience
2-macroglobulin extracting solution is transferred PH to 5.6-7.2, and distilled water is diluted to α
2The concentration of-macroglobulin is 7% (weight percent concentration), adds 0.005% thimerosal, filtration sterilization, and meat soup pipe antibacterial culturing is answered (one), and rabbit thermal source, toxicity test are answered (one), put sterilizing room after 10 days, and be no abnormal, is distributed into eye drop.
Embodiment 2: spissated α learnt from else's experience
2-macroglobulin extracting solution is transferred PH to 5.6-7.2, and distilled water is diluted to α
2The concentration of-macroglobulin is 2% (weight percent concentration), adds 0.03% nipalgin, filtration sterilization, and meat soup pipe antibacterial culturing should (one), and family exempts from thermal source, toxicity test should (one), and it is no abnormal after 10 days to put sterilizing room, is distributed into eye drop.
Embodiment 3: spissated α learnt from else's experience
2-macroglobulin extracting solution is transferred PH to 5.6-7.2, and deionized water is diluted to α
2-macroglobulin concentration is 10% (weight percent concentration), adds 0.01% bromo geramine, filtration sterilization, and meat soup pipe antibacterial culturing should (one), and rabbit thermal source, toxicity test should (one), and it is no abnormal after 10 days to put sterilizing room, is distributed into eye drop.
Claims (3)
1, a kind of eye drop, it is mainly by α
2-macroglobulin and distilled water or deionized water are formed, wherein α
2-macroglobulin weight percent content is 2-15%.
2, eye drop according to claim 1, wherein α
2-macroglobulin weight percent content optimum range is 5-8%.
3, eye drop according to claim 1 and 2 wherein contains micro-antiseptic, and this antiseptic is nipalgin or thimerosal or bromo geramine.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 94107398 CN1115253A (en) | 1994-07-18 | 1994-07-18 | Eye drops |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 94107398 CN1115253A (en) | 1994-07-18 | 1994-07-18 | Eye drops |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1115253A true CN1115253A (en) | 1996-01-24 |
Family
ID=5033010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 94107398 Pending CN1115253A (en) | 1994-07-18 | 1994-07-18 | Eye drops |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1115253A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998024466A1 (en) * | 1996-12-05 | 1998-06-11 | Alcon Laboratories, Inc. | THE USE OF INHIBITORS OF TGF-β'S FUNCTIONS TO AMELIORATE OCULAR PATHOLOGY |
-
1994
- 1994-07-18 CN CN 94107398 patent/CN1115253A/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998024466A1 (en) * | 1996-12-05 | 1998-06-11 | Alcon Laboratories, Inc. | THE USE OF INHIBITORS OF TGF-β'S FUNCTIONS TO AMELIORATE OCULAR PATHOLOGY |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR860001148B1 (en) | Method for preparing hyaluronic acid having pharmaceutical activity | |
US7618643B2 (en) | Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease | |
EP0809486B1 (en) | Bio-erodible ophthalmic shield | |
Marmer | Therapeutic and protective properties of the corneal collagen shield | |
US7169406B2 (en) | Growth factor delivery systems for the healing of wounds and the prevention of inflammation and disease | |
JPH0651638B2 (en) | Eye drops for corneal epithelial wound treatment | |
RU2357708C1 (en) | Method of cornea epithelium defect treatment by soft therapeutic contact lenses | |
CN1115253A (en) | Eye drops | |
CN101077347A (en) | Multifunctional membrane used for glaucoma post-operation and preparation method thereof | |
ATE325618T1 (en) | USE OF NERVE GROWTH FACTOR IN THE PRODUCTION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DISEASES OF THE INNER EYE TISSUES | |
RU2322243C1 (en) | Pharmaceutical composition for treatment of cornea injury | |
WO2009088118A1 (en) | Pharmaceutical composition for treating corneal wound comprising poly-gamma-glutamic acid | |
Gupta | Efficacy of miconazole in experimental keratomycosis | |
CN1254250C (en) | Chinese medicine for treating eye diseases and its prepn process | |
RU2172152C2 (en) | Surgical method for correcting residual myopia after performing keratotomy | |
RU2142257C1 (en) | Method for finishing eye implants and contact lenses | |
RU2122386C1 (en) | Method of treating corneal erosions after excimer-laser photo- refraction keratectomia | |
RU2163123C2 (en) | Ophthalmic drop | |
SU1463289A1 (en) | Method of akinesia of the eye | |
SU577031A1 (en) | 'benzodiocaine'anesthetic for ophtalmology and otolaryngology | |
CN1164327C (en) | Eye medicament | |
CN1459291A (en) | Eyedrops containing low molecular weight heparin, and its prepn. method | |
RU2575590C1 (en) | Method of treating recurrent corneal erosions | |
Laibson | AND RECURRENT EROSION | |
CN118252796A (en) | Eye drops containing L-ergothioneine and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C01 | Deemed withdrawal of patent application (patent law 1993) | ||
WD01 | Invention patent application deemed withdrawn after publication |